Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGHTEN: Tofogliflozin vs glimepiride on skeletal muscle mass in non-obese type 2 diabetes
jRCTs041240011Active, not recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Apr 2024
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Tofogliflozin arm with Glimepiride arm (2 arms). Started Apr 2024; status: active, not recruiting.
02
Drugs
tofogliflozinglimepiride
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs041240011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240011.